| Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Drug development in higher-risk myelodysplastic syndromes |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Treatment of lower-risk myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Diagnosis of myelodysplastic syndromes: the classic and the novel |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature |
|
Clinical Lymphoma, Myeloma & Leukemia |
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Efficacy and Safety of Inhibitors of the Proximal Pathway of the Complement System in Paroxysmal Nocturnal Hemoglobinuria: A Meta-analysis of Randomized Controlled Trials |
|
American Journal of Therapeutics |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
|
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
| Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
